文献速递心脏核医学

Discovery NM 530c半导体伽马相机心肌灌注显像中注射部位残留放射性药物活性所致伪影的消除

Elimination of artifacts caused by residual radiopharmaceutical activity in injection site in myocardial perfusion imaging on Discovery NM 530c semiconductor gamma camera.
PubMed 文献 · EJNMMI Res · 2025-03-28

研究纳入50例使用Discovery NM 530c伽马相机行心肌灌注显像的男性患者,评估注射部位残留放射性药物活性所致伪影对图像质量的影响及铅屏蔽消除伪影的可能性。覆盖注射部位后,约20%的研究SSS、SRS或SDS评估由正常变为异常或反之,最终诊断在近1/5患者中改变,最常见为消除先前可见的显著负荷诱导灌注缺损。

要点

  • 注射部位残留放射性药物活性更常见于负荷研究(84%病例)。
  • 铅屏蔽覆盖注射部位后,近20%研究的SSS、SRS或SDS评估发生正常与异常之间的改变。
  • 消除伪影改变近1/5患者的最终诊断,最常见为消除先前可见的显著负荷诱导灌注缺损。

核心结论

  • 注射部位放射性药物活性所致伪影降低图像质量,可能产生或掩盖灌注缺损。
  • 这些伪影可通过铅屏蔽消除,并可在20%患者中改变心肌灌注显像研究的最终评估。

研究设计与样本

  • 研究纳入50例因心肌灌注显像转诊的男性患者,使用Discovery NM 530c伽马相机,在负荷或静息研究中观察到注射部位放射性药物活性。
  • 此类情况下,用特殊铅屏蔽覆盖注射部位后,保持患者和相机位置不变,立即重复图像采集。
  • 图像由两名经验丰富的核医学医师采用0-4分评分法评估每个节段(0为正常灌注,4为完全无灌注),计算整个心肌和3个主要血管区域的SSS、SRS和SDS。

主要发现

  • SSS、SRS和SDS在右冠状动脉(RCA)区域最常被评估为异常。
  • 注射部位放射性药物活性更常见于负荷研究(84%病例)。
  • 用屏蔽覆盖注射部位后,近20%研究的SSS、SRS或SDS评估由正常变为异常或反之。
  • 最常受影响的血管区域为左前降支(LAD)和RCA。
  • 消除伪影改变近1/5患者的最终诊断,最常见为消除先前可见的显著负荷诱导灌注缺损;发生此类改变的患者在一年随访中未报告任何心血管事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac gamma cameras dedicated for myocardial perfusion imaging (MPI) perform studies faster and acquire higher quality images than traditional cameras. However, they are susceptible to some artifacts. We observed a previously unreported artifact, caused by residual radiopharmaceutical activity in injection site in cubital fossa caught in camera field of view. This study aims to assess the impact of these artifacts on image quality and the possibility of their elimination. Study included 50 male patients referred for MPI using Discovery NM 530c gamma camera, in whom radiopharmaceutical activity in injection site was observed in stress or rest study. In such cases, image acquisition was immediately repeated, with the patient and the camera kept in the same position, after covering the injection site with a special lead shield. Obtained images were assessed by two experienced nuclear medicine physicians using a 0-4 point scale in each segment (where 0-normal perfusion, and 4-complete lack of perfusion). Summed stress, rest and difference scores (SSS, SRS and SDS, respectively) were calculated for the entire myocardium and 3 main vascular territories. RESULTS: SSS, SRS and SDS were most frequently assessed as abnormal in RCA territory. Radiopharmaceutical activity in injection site was observed more frequently in stress studies (84% of cases). Covering injection site with a shield changed the assessment of SSS, SRS or SDS from normal to abnormal and vice versa in almost 20% of studies. The most frequently affected vascular territories were LAD and RCA. Elimination of the artifact changed final diagnosis in almost 1/5 of patients, most often by eliminating previously visible significant stress-induced perfusion defects (patients in whom such change occurred did not report any cardiovascular events in one-year follow-up). CONCLUSIONS: Artifacts caused by radiopharmaceutical activity in injection site reduce image quality and can potentially generate or hide perfusion defects. They can be observed mainly in patients examined in prone position, after radiopharmaceutical injection in cubital fossa. These artifacts can be eliminated by a lead shield, which can change the final assessment of MPI study in 20% of the patients.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Owczarek A, Adamczewski Z, Plachcinska A, et al. Elimination of artifacts caused by residual radiopharmaceutical activity in injection site in myocardial perfusion imaging on Discovery NM 530c semiconductor gamma camera. EJNMMI Res. 2025. PMID: 40153242. doi:10.1186/s13550-025-01222-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。